Skip to main content
OpenTrials
Completed

NCT Number: NCT05197842

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

The Second hospital Of Anhui Medical University, Hefei, Anhui, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years old≤Age≤75 years old, male or female;
  • Diagnosis of granulomatosis with polyangiitis(GPA) or microscopic polyangiitis(MPA);
  • Newly diagnosed or relapsed GPA or MPA that requires treatment with cyclophosphamide(CYC) and glucocorticoids(GCs);
  • Positive test for anti-proteinase 3(PR3) or anti-myeloperoxidase (MPO);
  • Estimated glomerular filtration rate ≥15 mL/minute/1.73 m^2;
  • At least 1 major item, or at least 3 non-major items, or at least the 2 renal items on BVAS;

Exclusion criteria

  • Active tuberculosis infection;
  • Severe disease as determined by rapidly progressive glomerulonephritis, alveolar hemorrhage requiring pulmonary ventilation support, rapid-onset mononeuritis multiplex or central nervous system involvement;
  • Any other known multi-system autoimmune disease including eosinophilic granulomatosis with polyangiitis (Churg-Strauss), systemic lupus erythematosus, IgA vasculitis (Henoch-Schönlein), rheumatoid vasculitis,anti-glomerular basement membrane disease, or cryoglobulinemic vasculitis;
  • HBsAg positive,or HBcAb positive and HBV-DNA positive;
  • Received CYC within 3 months before the first administration or Received rituximab(RTX) within 12 months before the first administration;
  • Received glucocorticoid shock therapy within 4 weeks before the first administration;
  • Received an oral daily dose of a GC of > 10 mg prednisone-equivalent for more than 6 weeks continuously before the first administration;
  • Received a anti-tumor necrosis factor and other biological agents treatment within 12 weeks before the first administration;
  • Received Continuous dialysis treatment for 12 weeks or more before the first administration; Received Dialysis within 1 week before the first administration;
  • Received intravenous immunoglobulin (Ig) or plasma exchange within 4 weeks before the first administration;
  • Pregnant or lactating.

Treatment and study plan

BDB-001 injection

Drug

Intravenously administered

Cyclophosphamide

Drug

Intravenously administered

Glucocorticoids

Drug

Orally administered

Other names: Prednisone

Primary outcomes

  1. The proportion of patients achieving disease complete remission or partial remission assessed by Birmingham Vasculitis Activity Score (BVAS)

    Time frame: 12 weeks

Secondary outcomes

  1. The proportion of patients achieving disease complete remission assessed by Birmingham Vasculitis Activity Score (BVAS)

    Time frame: 12 weeks

  2. Change from baseline in the Birmingham Vasculitis Activity Score (BVAS)

    Time frame: 4 weeks、8 weeks、12 weeks

  3. Change from baseline in the Vasculitis Damage Index (VDI)

    Time frame: 12 weeks

  4. Change from baseline in Estimated glomerular filtration rate (eGFR)、Urinary albumin:creatinine ratio (UACR)、Urine erythrocyte

    Time frame: 4 weeks、8 weeks、12 weeks

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: 0-24weeks

    Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients

  6. Number of Participants developing anti-BDB-001 antibodies.

    Time frame: 0-24weeks

    Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients

  7. Area under the plasma concentration versus time curve (AUC) of BDB-001.

    Time frame: 0-12 weeks

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

  8. Peak Plasma Concentration (Cmax) of BDB-001 and time to reach Cmax.

    Time frame: 0-12 weeks

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

  9. Minimal Plasma Concentration (Cmin) of BDB-001.

    Time frame: 0-12 weeks

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

  10. Terminal phase half-life.

    Time frame: 0-12 weeks

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

  11. Change from baseline in C5a (mg/dL) concentration.

    Time frame: 0-12 weeks

Sponsors and collaborators

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Industry

Registry information

Official study title

A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jan 20, 2022
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.